Table 7

Genes that have a general association (P-value < 0.05) with the progression-free glioblastoma survival

Gene Symbol

Probe Identifier

P-value

Hazard Ratio1

Relevant literature references


Pla2g7

206214_at

<.0001

0.11 (0.05-0.23)

[119]O

Pdgfb

216061_x_at

<.0001

0.18 (0.09-0.35)

[28]G

Calm2

207243_s_at

0.0011

0.22 (0.09-0.54)

[28]G

Timp3

201148_s_at

<.0001

0.26 (0.16-0.41)

[26]G

Agpat1

215535_s_at

<.0001

0.27 (0.15-0.51)

n/a

Ifngr1

202727_s_at

<.0001

0.32 (0.19-0.53)

[27]G

Pvr

214444_s_at

<.0001

0.32 (0.19-0.54)

[26]G

Ndufv1

208714_at

0.0002

0.33 (0.19-0.59)

n/a

Fgfr2

211401_s_at

<.0001

0.39 (0.26-0.57)

[26]G

E2f3

203693_s_at

<.0001

0.42 (0.29-0.60)

[28]G

Pold2

201115_at

0.0007

0.43 (0.27-0.70)

[26]G

Calm3

200622_x_at

0.0001

0.43 (0.28-0.67)

[28]G

Tp53

211300_s_at

<.0001

0.43 (0.29-0.64)

[25]G

Raf1

201244_s_at

0.0141

0.46 (0.25-0.85)

[26]G

Pknox2

219046_s_at

<.0001

0.46 (0.33-0.62)

[120]O

App

214953_s_at

0.0016

0.47 (0.30-0.75)

[24]G

Fstl1

208782_at

<.0001

0.47 (0.35-0.62)

[25]G

Camk2b

211483_x_at

0.0008

0.54 (0.38-0.77)

[28]G

Pten

204053_x_at

0.0003

0.60 (0.46-0.79)

[26]G

Mdm2

217373_x_at

<.0001

0.66 (0.57-0.76)

[26]G

Ccnd1

208711_s_at

0.0273

0.80 (0.66-0.98)

[28]G

Hspa1a/Hspa1b

202581_at

0.0529

0.82 (0.67-1. 00)

[24]G

Cd24

208650_s_at

0.0069

0.85 (0.75-0.95)

[121]O

Clec2b

209732_at

0.06452

1.19 (0.99-1.44)

[122]O

Cav2

203324_s_at

0.0024

1.25 (1.08-1.44)

[123]O

Snx10

218404_at

<.0001

1.34 (1.16-1.57)

[124]O

Wee1

215711_s_at

0.0083

1.37 (1.08-1.74)

[27]G

Hras

212983_at

0.08022

1.49 (0.95-2.33)

[85]G

Mns1

219703_at

0.0053

1.51 (1.13-2.02)

n/a

Ppp1r15a

37028_at

0.011

1.54 (1.10-2.15)

n/a

App

211277_x_at

0.08112

1.56 (0.95-2.56)

[24]G

Fadd

202535_at

0.09342

1.57 (0.93-2.65)

[125]O

Pik3r1

212239_at

0.018

1.60 (1.08-2.36)

[20]G

Mmp14

217279_x_at

0.0182

1.66 (1.09-2.52)

[24]G

Mtap

204956_at

0.0016

1.66 (1.21-2.27)

[26]G

Il13ra1

211612_s_at

0.0003

1.72 (1.28-2.32)

[24]G

Kcnj13

210179_at

0.0235

1.74 (1.08-2.82)

[126]O

Clip3

212358_at

0.0022

1.75 (1.22-2.50)

n/a

Aanat

207225_at

0.0114

1.78 (1.14-2.79)

[127]O

Camk2g

214322_at

0.0024

1.86 (1.24-2.78)

[56]G

Prkca

215195_at

0.0005

1.90 (1.32-2.73)

[28]G

Kdm6b

41386_i_at

0.0003

2.03 (1.39-2.96)

n/a

Zfy

207246_at

0.0016

2.06 (1.31-3.22)

[128]O

Smarcb1

212167_s_at

0.0004

2.06 (1.38-3.07)

[26]G

Utp20

209725_at

<.0001

2.08 (1.46-2.98)

n/a

Igl@

211655_at

0.0209

2.22 (1.13-4.38)

[129]O

Atf5

204998_s_at

<.0001

2.31 (1.72-3.11)

[130]G

Shox

207570_at

<.0001

2.66 (1.73-4.07)

[24]G

Loc283079

215929_at

0.0071

2.73 (1.31-5.69)

n/a

Ung

202330_s_at

0.0001

2.79 (1.66-4.68)

[27]G

Hnrnpd

213359_at

<.0001

2.94 (1.91-4.52)

n/a

Camk2b

209956_s_at

<.0001

3.02 (2.13-4.29)

[28]G

Timp3

201150_s_at

<.0001

3.10 (1.88-5.11)

[26]G

Nras

202647_s_at

<.0001

3.93 (2.60-5.95)

[28]G

Paics

214664_at

<.0001

5.28 (3.13-8.91)

[66]O


n/a, No association with any type of cancer found in literature;

1 Hazard ratio estimate (95% confidence interval);

2 Borderline significant (P-value < 0.1) included for completeness;

G Gene confirmed in an independent glioblastoma multiforme study; the number between square brackets denotes the corresponding literature reference;

O Gene confirmed in an independent study on any other type of cancer; the number between square brackets denotes the corresponding literature reference.

SerĂ£o et al. BMC Medical Genomics 2011 4:49   doi:10.1186/1755-8794-4-49

Open Data